

VCN Biosciences to present clinical data on systemic administration of VCN-01 in pancreatic cancer patients at 28th EORTC-NCI-AACR SYMPOSIUM on Molecular Targets & Cancer Therapeutics

November 14th, 2016 – VCN Biosciences, a clinical –stage company developing oncolytic immunoncology products, is pleased to announce that preliminary clinical data on the First-in-Man Phase 1 clinical trial of VCN-01 after a single intravenous injection, either alone or combined with nab-paclitaxel/gemcitabine will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, one of the world foremost oncology conferences on the latest developments in targets and drugs for cancer. Dr. Manuel Hidalgo MD, Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC) from Harvard Cancer Center and principal investigator of the clinical program with VCN-01 will present the poster in a special session called Poster in the Spotlight.

28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will bring together more than 2000 academics, researchers and pharmaceuticals industry representatives across the world to discuss latest innovations in oncology drug.

VCN Biosciences poster is titled: **"First-in-human dose-escalation study of VCN-01, a selective oncolytic adenovirus with hyaluronidase activity in patients with advanced or metastatic cancer"** (P128) and will be presented in a session to be held in the poster area on 30 November 2016 from 13:00 to 13:30.

We are extremely proud to have participated in bringing VCN-01 into the clinic, and are encouraged by the results from this clinical study", said Dr. Cascalló, Chief Executive Officer of VCN Biosciences. "VCN-01 has not only revealed a positive safety profile but also an ability to reach tumor cells after systemic administration and modify intratumor milieu. This is exciting because it can result in clinical efficacy for pancreatic cancer, a devastating tumor."